Donitriptan monohydrochloride
Donitriptan monohydrochloride structure
|
Common Name | Donitriptan monohydrochloride | ||
|---|---|---|---|---|
| CAS Number | 170911-68-9 | Molecular Weight | 439.94 | |
| Density | N/A | Boiling Point | 727.1ºC at 760 mmHg | |
| Molecular Formula | C23H26ClN5O2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 393.6ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.
Br. J. Pharmacol. 149(1) , 82-91, (2006) It has been suggested that during a migraine attack capsaicin-sensitive trigeminal sensory nerves release calcitonin gene-related peptide (CGRP), resulting in cranial vasodilatation and central nociception; hence, trigeminal inhibition may prevent this vasodi... |
|
|
Donitriptan (Pierre Fabre).
Curr. Opin. Investig. Drugs 2(3) , 415-8, (2001) Pierre Fabre is developing donitriptan, a piperazide 5-HT1D agonist, as a potential treatment for migraine [175854]. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development [396027]. This compound... |
|
|
Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs.
Cephalalgia 22(1) , 37-47, (2002) We investigated the effects of donitriptan, which possesses a uniquely high affinity and efficacy at 5-HT1B/1D receptors, on carotid and systemic haemodynamics in anaes thetized pigs. Donitriptan (0.16-100 microg kg(-1), i.v.) dose-dependently decreased total... |
|
|
Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries.
Eur. J. Pharmacol. 443(1-3) , 125-32, (2002) Donitriptan is a potent, high efficacy agonist at 5-HT(1B/1D) receptors. We investigated the contractile effects of donitriptan and sumatriptan on human isolated blood vessels of relevance to therapeutic efficacy in migraine (middle meningeal artery) and coro... |
|
|
An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.
Pain 92(1-2) , 101-6, (2001) Calcitonin gene related peptide (CGRP) released from the C-fibers projecting from the trigeminal ganglion to the meninges has been suggested to play a crucial role in the pathophysiology of headache, particularly migraine. In humans it has been shown that CGR... |
|
|
F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
J. Pharmacol. Exp. Ther. 290(1) , 83-95, (1999) F 11356 (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl] ben zonitrile) was designed to take advantage of the superior potency and efficacy characteristics of 5-hydroxytryptamine (5-HT) compared with tryptamine at 5-HT1B/1D receptors. F 1135... |
|
|
Therapies in development for the treatment of migraine.
Expert Opin. Investig. Drugs 11(12) , 1813-20, (2002) While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT(1B/1D)--the "triptan" class of drugs--dominate the market for migraine therapy and while still more triptans are under development, recent research efforts have also explor... |
|
|
Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: further insights into its mechanism of action relevant to headache relief.
J. Pharmacol. Exp. Ther. 305(2) , 749-54, (2003) The effects of donitriptan on systemic arterial-jugular venous oxygen saturation difference were evaluated in pentobarbitone-anesthetized pigs. Oxygen and carbon dioxide partial pressures in systemic arterial and jugular venous blood as well as hemoglobin oxy... |
|
|
Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: an overlooked mechanism of antimigraine action?
J. Pharmacol. Exp. Ther. 315(2) , 849-57, (2005) The aim of the present study was to determine whether donitriptan and sumatriptan decreased jugular venous oxygen saturation and increased carbon dioxide partial pressure in venous blood. However, previous studies conducted with these compounds cannot discrim... |